Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs

Treatment of pain in rheumatoid arthritis must take into account the gastrointestinal and cardiovascular risk of individual patients. Adequate results are not yet available, and until they are, treatment recommendations must take into account, not only the more favourable gastrointestinal risk profi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of the rheumatic diseases 2006-01, Vol.65 (1), p.7-13
1. Verfasser:	Bolten, W W
Format:	Artikel
Sprache:	eng
Schlagworte:	acetylsalicylic acid Adenoma Prevention with Celecoxib Adenomatous Polyp Prevention on Vioxx Anti-Inflammatory Agents, Non-Steroidal - adverse effects APC APPROVe ASA Atherosclerosis - chemically induced atherothrombotic risk bid Biological and medical sciences Blood Platelets - drug effects Blood Platelets - metabolism CABG cardiovascular Celecoxib Long term Arthritis Safety Study CLASS confidence interval Confidence intervals Coronary Artery Bypass Graft COX-2 COX-2 inhibitors cyclo-oxygenase-2 Cyclooxygenase 2 Inhibitors - adverse effects Cyclooxygenase Inhibitors - adverse effects Diseases of the osteoarticular system Drug dosages gastrointestinal Heart attacks Humans Hypertension intravenous Medical sciences Mortality myocardial infarction non-steroidal anti-inflammatory drugs NSAIDs PGI2 PPI PreSAP Prevention of Spontaneous Adenoma Polyps prostaglandin I2 proton pump inhibitor Review rheumatoid arthritis Side effects Studies TARGET Therapeutic Arthritis Research and Gastrointestinal Event Trial three times a day Thrombosis - chemically induced thromboxane A2 Thromboxane A2 - metabolism tid twice a day TXA2 Ulcers VIGOR Vioxx Gastrointestinal Outcomes Research
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Treatment of pain in rheumatoid arthritis must take into account the gastrointestinal and cardiovascular risk of individual patients. Adequate results are not yet available, and until they are, treatment recommendations must take into account, not only the more favourable gastrointestinal risk profile of selective COX-2 inhibitors, but also the potential atherothrombotic risk of any NSAID or selective COX-2 inhibitor treatment.
ISSN:	0003-4967 1468-2060
DOI:	10.1136/ard.2005.036269